Geode Capital Management’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.57M | Sell |
1,322,013
-1,268,416
| -49% | -$2.35M | ﹤0.01% | 3047 |
|
|
2026
Q1 | $3.11M | Buy |
2,590,429
+122,081
| +5% | +$149K | ﹤0.01% | 2956 |
|
|
2025
Q4 | $2.43M | Sell |
2,468,348
-61,864
| -2% | -$74.3K | ﹤0.01% | 3095 |
|
|
2025
Q3 | $3.19M | Buy |
2,530,212
+101,045
| +4% | +$109K | ﹤0.01% | 3006 |
|
|
2025
Q2 | $2.72M | Buy |
2,429,167
+159,558
| +7% | +$185K | ﹤0.01% | 3034 |
|
|
2025
Q1 | $1.79M | Buy |
2,269,609
+42,642
| +2% | +$52.3K | ﹤0.01% | 3081 |
|
|
2024
Q4 | $3.68M | Sell |
2,226,967
-31,279
| -1% | -$78.8K | ﹤0.01% | 2892 |
|
|
2024
Q3 | $7.91M | Buy |
2,258,246
+10,863
| +0.5% | +$42.3K | ﹤0.01% | 2507 |
|
|
2024
Q2 | $7.37M | Buy |
2,247,383
+341,400
| +18% | +$1.49M | ﹤0.01% | 2508 |
|
|
2024
Q1 | $14M | Buy |
1,905,983
+42,498
| +2% | +$263K | ﹤0.01% | 2125 |
|
|
2023
Q4 | $6.97M | Buy |
1,863,485
+88,141
| +5% | +$208K | ﹤0.01% | 2531 |
|
|
2023
Q3 | $3.76M | Buy |
1,775,344
+30,232
| +2% | +$100K | ﹤0.01% | 2785 |
|
|
2023
Q2 | $8.31M | Buy |
1,745,112
+132,523
| +8% | +$731K | ﹤0.01% | 2397 |
|
|
2023
Q1 | $9.19M | Buy |
1,612,589
+48,298
| +3% | +$291K | ﹤0.01% | 2303 |
|
|
2022
Q4 | $15.8M | Buy |
1,564,291
+64,611
| +4% | +$1.21M | ﹤0.01% | 1933 |
|
|
2022
Q3 | $33.6M | Buy |
1,499,680
+34,002
| +2% | +$982K | 0.01% | 1373 |
|
|
2022
Q2 | $36.3M | Sell |
1,465,678
-8,549
| -0.6% | -$236K | 0.01% | 1335 |
|
|
2022
Q1 | $57.2M | Buy |
1,474,227
+48,259
| +3% | +$1.87M | 0.01% | 1152 |
|
|
2021
Q4 | $83.4M | Buy |
1,425,968
+21,872
| +2% | +$1.24M | 0.01% | 933 |
|
|
2021
Q3 | $83.2M | Sell |
1,404,096
-14,310
| -1% | -$1.12M | 0.01% | 918 |
|
|
2021
Q2 | $123M | Buy |
1,418,406
+69,094
| +5% | +$5.57M | 0.02% | 697 |
|
|
2021
Q1 | $111M | Buy |
1,349,312
+189,798
| +16% | +$18.2M | 0.02% | 704 |
|
|
2020
Q4 | $105M | Buy |
1,159,514
+56,024
| +5% | +$3.48M | 0.02% | 667 |
|
|
2020
Q3 | $44.1M | Buy |
1,103,490
+72,164
| +7% | +$2.52M | 0.01% | 988 |
|
|
2020
Q2 | $35.4M | Buy |
1,031,326
+82,538
| +9% | +$2.46M | 0.01% | 1094 |
|
|
2020
Q1 | $21.1M | Buy |
948,788
+71,953
| +8% | +$1.82M | 0.01% | 1256 |
|
|
2019
Q4 | $17.2M | Buy |
876,835
+64,302
| +8% | +$1.02M | ﹤0.01% | 1661 |
|
|
2019
Q3 | $12.6M | Buy |
812,533
+9,580
| +1% | +$184K | ﹤0.01% | 1776 |
|
|
2019
Q2 | $16.3M | Buy |
802,953
+12,082
| +2% | +$218K | ﹤0.01% | 1621 |
|
|
2019
Q1 | $13.9M | Buy |
790,871
+88,692
| +13% | +$1.4M | ﹤0.01% | 1677 |
|
|
2018
Q4 | $9.01M | Buy |
702,179
+186,927
| +36% | +$2.61M | ﹤0.01% | 1846 |
|
|
2018
Q3 | $8.39M | Buy |
515,252
+62,326
| +14% | +$737K | ﹤0.01% | 2046 |
|
|
2018
Q2 | $5.14M | Buy |
452,926
+48,292
| +12% | +$532K | ﹤0.01% | 2306 |
|
|
2018
Q1 | $3.95M | Buy |
404,634
+57,061
| +16% | +$547K | ﹤0.01% | 2390 |
|
|
2017
Q4 | $2.12M | Buy |
347,573
+45,142
| +15% | +$201K | ﹤0.01% | 2715 |
|
|
2017
Q3 | $1.2M | Buy |
302,431
+125,349
| +71% | +$426K | ﹤0.01% | 3038 |
|
|
2017
Q2 | $573K | Buy |
177,082
+57,568
| +48% | +$221K | ﹤0.01% | 3312 |
|
|
2017
Q1 | $543K | Buy |
119,514
+4,098
| +4% | +$15K | ﹤0.01% | 3278 |
|
|
2016
Q4 | $289K | Buy |
115,416
+7,323
| +7% | +$19.6K | ﹤0.01% | 3467 |
|
|
2016
Q3 | $337K | Buy |
108,093
+64
| +0.1% | +$155 | ﹤0.01% | 3411 |
|
|
2016
Q2 | $183K | Hold |
108,029
| – | – | ﹤0.01% | 3620 |
|
|
2016
Q1 | $194 | Sell |
108,029
-64
| -0.1% | -$132 | ﹤0.01% | 3646 |
|
|
2015
Q4 | $364K | Buy |
108,093
+128
| +0.1% | +$538 | ﹤0.01% | 3415 |
|
|
2015
Q3 | $575K | Buy |
107,965
+30,018
| +39% | +$205K | ﹤0.01% | 3164 |
|
|
2015
Q2 | $504K | Buy |
77,947
+46,371
| +147% | +$277K | ﹤0.01% | 3190 |
|
|
2015
Q1 | $154K | Buy |
31,576
+192
| +0.6% | +$952 | ﹤0.01% | 3661 |
|
|
2014
Q4 | $157K | Buy |
31,384
+192
| +0.6% | +$847 | ﹤0.01% | 3672 |
|
|
2014
Q3 | $160K | Buy |
31,192
+7,528
| +32% | +$43.6K | ﹤0.01% | 3645 |
|
|
2014
Q2 | $149K | Sell |
23,664
-64
| -0.3% | -$451 | ﹤0.01% | 3602 |
|
|
2014
Q1 | $231K | Buy |
+23,728
| New | +$183K | ﹤0.01% | 3454 |
|
Other funds holding FATE
JJ
Geode Capital Management's FATE Position: Q2 2026 in Review
Geode Capital Management reduced its Fate Therapeutics (FATE) stake by 49% in Q2 2026, selling an estimated $2.35M and leaving 1,322,013 shares worth $3.57M. The position accounts for ﹤0.01% of the portfolio, ranked #3047.
Geode Capital Management first reported a position in FATE in Q1 2014 and has held it in 50 quarters since. The position peaked at $123M in Q2 2021. 141 funds tracked by Wall St. Rank hold FATE as of Q2 2026.
- Geode Capital Management held 1,322,013 shares of Fate Therapeutics worth $3.57M as of Q2 2026.
- Geode Capital Management sold 1,268,416 Fate Therapeutics shares in Q2 2026, an estimated $2.35M.
- Fate Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3047 holding.
- Geode Capital Management first reported a position in Fate Therapeutics in Q1 2014 and has held it in 50 quarters since.
- Geode Capital Management's Fate Therapeutics position peaked at $123M in Q2 2021.
- 141 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.